BLB&B Advisors LLC continued to hold its position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,343 shares of the biopharmaceutical company’s stock at the end of the second quarter. BLB&B Advisors LLC’s holdings in Shire PLC were worth $234,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of SHPG. BlackRock Inc. boosted its position in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Glenview Capital Management LLC acquired a new position in shares of Shire PLC during the first quarter valued at about $176,927,000. Boston Partners boosted its position in shares of Shire PLC by 80.7% in the first quarter. Boston Partners now owns 1,359,151 shares of the biopharmaceutical company’s stock valued at $236,805,000 after buying an additional 606,814 shares during the last quarter. Jana Partners LLC acquired a new position in shares of Shire PLC during the first quarter valued at about $94,903,000. Finally, New South Capital Management Inc. acquired a new position in shares of Shire PLC during the first quarter valued at about $87,954,000. Institutional investors own 21.04% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) opened at 153.87 on Thursday. The stock has a market capitalization of $45.83 billion, a price-to-earnings ratio of 157.82 and a beta of 1.60. The company’s 50 day moving average is $165.41 and its 200-day moving average is $172.82. Shire PLC has a 1-year low of $153.43 and a 1-year high of $209.22.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company had revenue of $3.75 billion for the quarter. During the same quarter in the prior year, the firm earned $3.38 earnings per share. Shire PLC’s revenue for the quarter was up 54.2% compared to the same quarter last year. Equities analysts anticipate that Shire PLC will post $14.92 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/08/10/blbb-advisors-llc-maintains-position-in-shire-plc-nasdaqshpg-updated-updated.html.
Several research analysts have issued reports on SHPG shares. Zacks Investment Research cut shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub cut shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Saturday, July 1st. Goldman Sachs Group, Inc. (The) reiterated a “conviction-buy” rating on shares of Shire PLC in a research note on Friday, April 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $221.00 target price on shares of Shire PLC in a research note on Tuesday, April 18th. Finally, HSBC Holdings plc cut shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $222.27.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.